2. Search Result
Search Result
Results for "

TH17

" in MedChemExpress (MCE) Product Catalog:

77

Inhibitors & Agonists

1

Fluorescent Dye

4

Peptides

5

Inhibitory Antibodies

6

Natural
Products

1

Isotope-Labeled Compounds

1

Click Chemistry

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12776
    GSK805
    4 Publications Verification

    		 ROR Inflammation/Immunology
    GSK805 is an orally active and CNS penetrant RORγt inhibitor. GSK805 inhibits RORγ and Th17 cells differentiation with pIC50 values of 8.4 and >8.2. GSK805 inhibits the function of Th17 cells. GSK805 can be used for the research of immunity .
    GSK805
  • HY-125801
    3-Oxo-5β-cholanoic acid
    1 Publications Verification

    DehydroliTHocholic acid; 3-oxoLCA

    		 ROR Inflammation/Immunology
    3-Oxo-5β-cholanoic acid (Dehydrolithocholic acid), a bile acid metabolite, inhibits the diferentiation of TH17 cells by directly binding to the key transcription factor RORγt (Kd=1.13 μM) .
    3-Oxo-5β-cholanoic acid
  • HY-113238F
    FITC-Lithocholic acid 3-sulfate

    FITC-SulfoliTHocholic acid

    		 Fluorescent Dye Others
    FITC-Lithocholic acid 3-sulfate (FITC-Sulfolithocholic acid) is a FITC-labeled Lithocholic acid 3-sulfate, which is a sulfated biliary metabolite. Lithocholic acid 3-sulfate selectively inhibits Th17 cell differentiation by targeting RORγt. Lithocholic acid 3-sulfate can be used for the research of pathogenesis of cholestatic liver diseases .
    FITC-Lithocholic acid 3-sulfate
  • HY-P99256
    Tildrakizumab

    SCH 900222; MK 3222; Anti-Human IL23 Recombinant Antibody

    		 Interleukin Related Inflammation/Immunology Cancer
    Tildrakizumab (SCH 900222) is a humanized anti-IL-23 (p19 subunit) monoclonal antibody. IL-23 is a critical cytokine to maintain the Th17 cell phenotype. Tildrakizumab has high-affinity for single-chain IL-23 (Kd: 136 pM). Tildrakizumab is effective against moderate to severe plaque psoriasis .
    Tildrakizumab
  • HY-139780
    JNJ-61803534

    		ROR Inflammation/Immunology
    JNJ-61803534 is a potent and orally active RORγt inverse agonist with an IC50 of 9.6  nM. JNJ-61803534 has anti-inflammatory activity. JNJ-61803534 inhibits IL-17A production in human CD4+ T cells under Th17 differentiation conditions .
    JNJ-61803534
  • HY-101871
    Trehalose 6-behenate

    		TNF Receptor Inflammation/Immunology
    Trehalose 6-behenate is a Th1/Th17 skewing vaccine adjuvant.
    Trehalose 6-behenate
  • HY-155487
    JTE-151

    		ROR Neurological Disease Inflammation/Immunology
    JTE-151 is a RORγ inhibitor, which can suppress overactive immune response through inhibition of RORγ related to the activation of Th17 cells, making JTE-151 possible to be used in autoimmune disease research .
    JTE-151
  • HY-126252
    A-9758

    		ROR Interleukin Related Inflammation/Immunology
    A-9758 is a RORγ ligand and a potent, selective RORγt inverse agonist (IC50=5 nM), and exhibits robust potency against IL-17A release. A-9758 is effective in suppressing both Th17 differentiation and Th17 effector function. A-9758 significantly attenuates IL-23 driven psoriasiform dermatitis and is effective in blocking skin and joint inflammation .
    A-9758
  • HY-142703
    RORγt inverse agonist 28

    		ROR Inflammation/Immunology
    RORγt inverse agonist 28 is a potent reverse agonist of RORγt. RORγt inverse agonist 28 regulates the differentiation of Th17 cells and inhibits the production of IL-17. RORγt inverse agonist 28 has the potential for the research of inflammation and autoimmune diseases (extracted from patent WO2021228215A1, compound 6) .
    RORγt inverse agonist 28
  • HY-142806
    RORγt inverse agonist 26

    		ROR Inflammation/Immunology
    RORγt inverse agonist 26 is a potent reverse agonist of RORγt. RORγt inverse agonist 26 regulates the differentiation of Th17 cells and inhibits the production of IL-17. RORγt inverse agonist 26 has the potential for the research of inflammation and autoimmune diseases (extracted from patent WO2021228215A1, compound 1) .
    RORγt inverse agonist 26
  • HY-145809
    FASN-IN-5

    		Fatty Acid Synthase (FASN) Metabolic Disease Inflammation/Immunology Cancer
    FASN-IN-5 (example 11), a FASN inhibitor, can be used for the research of TH17- or CSF1 -mediated disease or disorder such as cancer, immunological disorders, and obesity .
    FASN-IN-5
  • HY-162490
    TF-S14

    		ROR Inflammation/Immunology
    TF-S14 is a reverse agonist of RORγt. TF-S14 reduces Th17 cell-associated cytokine production, including IL-17A, IL-21, and IL-22 by binding to and inhibiting RORγt activity. TF-S14 can be used in the study of autoimmune diseases and rejection in allotransplantation .
    TF-S14
  • HY-130243
    RORγt Inverse agonist 6

    		ROR Inflammation/Immunology
    RORγt Inverse agonist 6 (compound 43) is a RORγt inverse agonist for the study of Th17-driven autoimmune diseases. RORγt Inverse agonist 6 (compound 43) suppresses IL-17A gene expression by IL-23 stimulation in vivo .
    RORγt Inverse agonist 6
  • HY-N7501
    Isoformononetin
    1 Publications Verification

    		 Others Metabolic Disease Inflammation/Immunology
    Isoformononetin is an analog of Daidzein (HY-N0019) and has immunoprotective effects. Isoformononetin inhibits the differentiation of Th17 and B-cells lymphopoesis to promote osteogenesis in estrogen-deficient bone loss conditions .
    Isoformononetin
  • HY-142937
    RORγt agonist 2

    		ROR Inflammation/Immunology
    RORγt agonist 2 is a potent agonist of RORγt. RORγt agonist 2 promotes the differentiation of Th17 cells and enhances the levels of pro-inflammatory cytokines, thereby increasing the cytotoxicity of lymphocytes. RORγt agonist 2 inhibits the production of regulatory T cells, which suppresses the immune response (extracted from patent WO2021136339A1, compound 17) .
    RORγt agonist 2
  • HY-142938
    RORγt agonist 3

    		ROR Inflammation/Immunology
    RORγt agonist 3 is a potent agonist of RORγt. RORγt agonist 3 promotes the differentiation of Th17 cells and enhances the levels of pro-inflammatory cytokines, thereby increasing the cytotoxicity of lymphocytes. RORγt agonist 3 inhibits the production of regulatory T cells, which suppresses the immune response (extracted from patent WO2021136326A1, compound 23) .
    RORγt agonist 3
  • HY-112863
    RORγt inhibitor 3

    		ROR Inflammation/Immunology
    RORγt inhibitor 3 is an orally active and potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitor. RORγt inhibitor 3 shows high binding affinity and inhibitory activity of Th17 cell differentiation. RORγt inhibitor 3 also shows efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models .
    RORγt inhibitor 3
  • HY-120785
    SR1555

    		ROR Inflammation/Immunology
    SR1555 is a specific retinoic acid receptor-related orphan nuclear receptor γ (RORγ) inverse agonist with an IC50 value of 1 μM. SR1555 not only inhibits TH17 cell development and function but also increases the frequency of T regulatory cells, as well as inhibits the expression of IL-17. SR1555 can be used for researching autoimmune diseases .
    SR1555
  • HY-W011220
    Ciglitazone
    1 Publications Verification

    ADD-3878; U-63287

    		 PPAR Cardiovascular Disease Cancer
    Ciglitazone is a potent and selective PPARγ agonist (EC50=3 μM). Ciglitazone inhibits proliferation and differentiation of th17 cells. Ciglitazone is a hypoglycemic agent orally active in the obese-hyperglycemic animal models. Ciglitazone induces apoptosis accompanied by activation of p38 MAPK and nuclear translocation of apoptosis inducing factor (AIF) in opossum kidney (OK) renal epithelial cells .
    Ciglitazone
  • HY-N2279
    Kurarinone
    3 Publications Verification

    		 Eukaryotic Initiation Factor (eIF) Inflammation/Immunology Cancer
    Kurarinone is an orally active flavonoid isolated from matrine that inhibits the pathogenesis of experimental autoimmune encephalomyelitis by inhibiting cell differentiation of Th1 and Th17. Kurarinone has antitumor and anti-inflammatory activity .
    Kurarinone
  • HY-P991274
    BMS-986010

    		Interleukin Related Inflammation/Immunology
    BMS-986010 is a monoclonal antibody inhibitor targeting the p19 subunit of interleukin-23 (IL-23). BMS-986010 reduces IL-23-induced STAT3 phosphorylation and inhibits Th17 cell differentiation and the release of proinflammatory cytokines (such as IL-17 and TNF-α). BMS-986010 is promising for research of autoimmune diseases such as psoriasis and Crohn's disease .
    BMS-986010
  • HY-160040A
    Cobitolimod sodium

    		Toll-like Receptor (TLR) Inflammation/Immunology
    Cobitolimod sodium is a DNA oligonucleotide agonist of TLR-9 with anti-inflammatory activity. Cobitolimod sodium inhibits Th17 cells and induces anti-inflammatory FoxP3 and IL-10 expression, inhibiting the IL-17 signaling pathway .
    Cobitolimod sodium
  • HY-160040
    Cobitolimod

    		Toll-like Receptor (TLR) Inflammation/Immunology
    Cobitolimod is a DNA oligonucleotide agonist of TLR-9 with anti-inflammatory activity. Cobitolimod suppresses Th17 cells and induces anti-inflammatory FoxP3 and IL-10 expression, inhibiting the IL-17 signaling pathway .
    Cobitolimod
  • HY-125801R
    3-Oxo-5β-cholanoic acid (Standard)

    DehydroliTHocholic acid (Standard); 3-oxoLCA (Standard)

    		 ROR Inflammation/Immunology
    3-Oxo-5β-cholanoic acid (Standard) is the analytical standard of 3-Oxo-5β-cholanoic acid. This product is intended for research and analytical applications. 3-Oxo-5β-cholanoic acid (Dehydrolithocholic acid), a bile acid metabolite, inhibits the diferentiation of TH17 cells by directly binding to the key transcription factor RORγt (Kd=1.13 μM)[1].
    3-Oxo-5β-cholanoic acid (Standard)
  • HY-120225
    NJK14047

    		p38 MAPK Inflammation/Immunology
    NJK14047 inhibits p38 MAPK and the differentation of naive T-cells to Th1 and Th17 cells. NJK14047 ameliorates the collage-induced rheumatoid arthritis and Imiquimod (HY-B0180)-induced psoriasis in mice .
    NJK14047
  • HY-P99396
    Spesolimab

    BI 655130

    		 Interleukin Related Inflammation/Immunology
    Spesolimab (BI 655130) is a mouse-derived humanized IgG1k antibody against IL-36R. IL-36 plays an important role in the immune system and Spesolimab is being investigated in palmoplantar pustulosis (PPP). Spesolimab was associated with a reduction in biomarkers associated with the innate, Th1/Th17 and neutrophil pathways .
    Spesolimab
  • HY-15826
    SGC-CBP30
    10+ Cited Publications

    		 Epigenetic Reader Domain Histone Acetyltransferase Inflammation/Immunology Cancer
    SGC-CBP30 is a potent and highly selective CBP/p300 bromodomain (Kds of 21 nM and 32 nM for CBP and p300, respectively) inhibitor, displaying 40-fold selectivity over the first bromodomain of BRD4 [BRD4(1)] bound. SGC-CBP30 strongly reduces secretion of IL-17A in Th17 cells and has anti-inflammatory effects .
    SGC-CBP30
  • HY-W010520
    Methylisothiazolinone

    		Bacterial MMP Apoptosis Fungal Infection Inflammation/Immunology
    Methylothiazolinone is a bacterial and fungal inhibitor and preservative, as well as a sensitizer. Methylisothiazolinone can activate matrix metalloproteinases (MMPs) in human bronchial epithelial cells to induce apoptosis and inflammatory response. Methylisothiazolinone can promote the development of atopic dermatitis in mice by disrupting Th2/Th17 related immune responses. Methylisothiazolinone can cause mitochondrial damage in the endothelium of rat cerebral blood vessels .
    Methylisothiazolinone
  • HY-N7501R
    Isoformononetin (Standard)

    		Others Metabolic Disease Inflammation/Immunology
    Isoformononetin (Standard) is the analytical standard of Isoformononetin. This product is intended for research and analytical applications. Isoformononetin is an analog of Daidzein (HY-N0019) and has immunoprotective effects. Isoformononetin inhibits the differentiation of Th17 and B-cells lymphopoesis to promote osteogenesis in estrogen-deficient bone loss conditions .
    Isoformononetin (Standard)
  • HY-N7501S
    Isoformononetin-d3

    		Isotope-Labeled Compounds Inflammation/Immunology
    Isoformononetin-d3 is the deuterium labeled Isoformononetin (HY-N7501). Isoformononetin is an analog of Daidzein (HY-N0019) and has immunoprotective effects. Isoformononetin inhibits the differentiation of Th17 and B-cells lymphopoesis to promote osteogenesis in estrogen-deficient bone loss conditions .
    Isoformononetin-d3
  • HY-103637
    Vimirogant

    VTP-43742

    		 ROR Inflammation/Immunology
    Vimirogant (VTP-43742) is a potent, selective, and orally active RORγt inhibitor (Ki=3.5 nM; IC50=17 nM). Vimirogant exhibits >1000-fold selectivity versus the RORα and RORβ isotypes. Vimirogant inhibits Th17 differentiation and IL-17A secretion from mouse splenocytes (IC50=57 nM) without affecting Th1, Th2, or Treg cell differentiation. Vimirogant has the potential for autoimmune disorders research .
    Vimirogant
  • HY-103637A
    Vimirogant hydrochloride
    1 Publications Verification

    VTP-43742 hydrochloride

    		 ROR Inflammation/Immunology
    Vimirogant (VTP-43742) hydrochloride is a potent, selective, and orally active RORγt inhibitor (Ki=3.5 nM; IC50=17 nM). Vimirogant hydrochloride exhibits >1000-fold selectivity versus the RORα and RORβ isotypes. Vimirogant hydrochloride inhibits Th17 differentiation and IL-17A secretion from mouse splenocytes (IC50=57 nM) without affecting Th1, Th2, or Treg cell differentiation. Vimirogant hydrochloride has the potential for autoimmune disorders research .
    Vimirogant hydrochloride
  • HY-W010520R
    Methylisothiazolinone (Standard)

    		Reference Standards Bacterial MMP Infection Inflammation/Immunology
    Methylisothiazolinone (Standard) is the analytical standard of Methylisothiazolinone. Methylothiazolinone is a fungicide and preservative, as well as a sensitizer. Methylisothiazolinone can activate matrix metalloproteinases (MMPs) in human bronchial epithelial cells to induce cell apoptosis and inflammatory response. Methylisothiazolinone can promote the development of atopic dermatitis in mice by disrupting Th2/Th17 related immune responses. Methylisothiazolinone can cause mitochondrial damage in the endothelium of rat cerebral blood vessels .
    Methylisothiazolinone (Standard)
  • HY-P4790
    Acetyl-Exenatide

    		PI3K Akt Metabolic Disease
    Acetyl-Exenatideyes is an acetylated derivative of Exenatide. Exenatide has the function similar to insulin, which can be used for research of type 2 diabetes. Exenatide can promote Th17 differentiation, inhibits Tregs differentiation, downregulates PI3K/Akt/FoxO1 phosphorylation .
    Acetyl-Exenatide
  • HY-126037
    (±)-ML 209
    1 Publications Verification

    		 ROR Inflammation/Immunology
    (±)-ML 209 (compound 4n), a diphenylpropanamide, is a retinoic acid-related orphan receptor RORγ antagonist with an IC50 of 1.1 μM. (±)-ML 209 inhibits RORγt transcriptional activity with an IC50 of 300 nM in HEK293t cells. (±)-ML 209 inhibits the transcriptional activity of RORγt, but not RORα in cells. (±)-ML 209 selectively inhibits murine Th17 cell differentiation without affecting the differentiation of naïve CD4 + T cells into other lineages, including Th1 and regulatory T cells .
    (±)-ML 209
  • HY-P10408
    Candidalysin

    		EGFR MMP Calcium Channel NOD-like Receptor (NLR) ERK p38 MAPK Infection Inflammation/Immunology
    Candidalysin is a cytolytic peptide toxin secreted by the fungus Candida albicans. Candidalysin drives epithelial immune responses by activating the EGFR-MAPK signaling pathway, inducing MMP expression and calcium influx, and regulating the c-Fos transcription factor and MKP1 via p38 MAPK and ERK1/2 respectively. Candidalysin is essential for mucosal and systemic infections, activating NLRP3 to promote inflammatory responses, neutrophil recruitment, and Th17 immunity. Candidalysin activates LDH causing membrane damage and exhibiting cytotoxicity
    Candidalysin
  • HY-120785A
    SR1555 hydrochloride

    		ROR Inflammation/Immunology
    SR1555 hydrochloride is the hydrochloride salt form of SR1555 (HY-120785). SR1555 hydrochloride is an inverse agonist for retinoic acid receptor-related orphan nuclear receptor γ (RORγ) with an IC50 of 1 μM. SR1555 hydrochloride inhibits the development and function of pro-inflammatory TH17 cell, increases the frequency of anti-inflammatory T regulatory (Treg) cells. SR1555 hydrochloride can be used for research about autoimmune diseases .
    SR1555 hydrochloride
  • HY-155680
    BET BD2-IN-1

    		Epigenetic Reader Domain Inflammation/Immunology
    BET BD2-IN-1 (compound 45) is a potent and selective inhibitor of BET BD2 (IC50=1.6 nM). BET BD2-IN-1 inhibits the differentiation of Th17 cells by decreasing the activation of STAT3 and NF-κB. BET BD2-IN-1 is used in psoriasis and inflammatory bowel disease (IBD) research .
    BET BD2-IN-1
  • HY-138115
    7ß,27-Dihydroxycholesterol

    7β, 27-OHC

    		 ROR Inflammation/Immunology
    7ß,27-Dihydroxycholesterol (7β, 27-OHC) is a potent and selective activator of RORγt (Ki=120 nM). 7ß,27-Dihydroxycholesterol promotes the differentiation of mouse and human CD4 + Th17 cells. 7ß,27-Dihydroxycholesterol also increases the production of IL-17 depended on CYP27A1 .
    7ß,27-Dihydroxycholesterol
  • HY-164455
    AJI-214

    		STAT JAK Aurora Kinase Mitosis Inflammation/Immunology
    AJI-214 is a dual-target inhibitor of Aurora kinase A and JAK2. AJI-214 directly blocks Aurora kinase A to inhibit T cell mitotic progression and cell polarity, and inhibits JAK2 activation to inhibit STAT3 phosphorylation, thereby reducing the differentiation of TH1 and TH17 cells. AJI-214 can be used in studies on regulating immune responses and preventing graft-versus-host disease (GVHD) .
    AJI-214
  • HY-155505
    AHR agonist 4

    		Aryl Hydrocarbon Receptor Inflammation/Immunology
    AHR agonist 4 (compound 24e) is an agonist of Aryl hydrocarbon receptor (AHR), assocaited with the immune balance of Th17/22 and Treg cells. AHR agonist 4 serves as a lead compound for anti-psoriasis drug, alleviates imiquimod (IMQ)-induced psoriasis-like skin lesion . AHR agonist 4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    AHR agonist 4
  • HY-145491
    Resolvin D5

    		ERK NF-κB Inflammation/Immunology
    Resolvin D5 is a prolytic mediator (SPM) with anti-inflammatory activity derived from oxidized lipids DHA. Resolvin D5 inhibits Th17 cell differentiation and promotes regulatory T cell differentiation, and inhibits CD4+ T cell proliferation. Resolvin D5 attenuates osteoclast differentiation and interferes with osteoclastogenesis. Resolvin D5 also regulates ERK phosphorylation and nuclear translocation of NF-kappaB. Resolvin D5 could be used in rheumatoid arthritis research .
    Resolvin D5
  • HY-164454
    AJI-100

    		Aurora Kinase STAT JAK Mitosis Inflammation/Immunology
    AJI-100 is a dual-target inhibitor of Aurora kinase A and JAK2 with IC50 values of 12.7 nM and 18.5 nM, respectively. AJI-100 directly blocks Aurora kinase A to inhibit T cell mitosis and cell polarity, and inhibits JAK2 activation to inhibit STAT3 phosphorylation, thereby reducing the differentiation of TH1 and TH17 cells. AJI-100 can be used in studies on regulating immune responses and preventing graft-versus-host disease (GVHD) .
    AJI-100
  • HY-100754C
    Ritlecitinib tosylate
    5+ Cited Publications

    PF-06651600 tosylate

    		 JAK Interleukin Related STAT Inflammation/Immunology
    Ritlecitinib (PF-06651600) tosylate is a highly selective, orally active, irreversible covalent JAK3 inhibitor (IC50=33 nM) without inhibitory activity towards JAK1, JAK2, and TYK2 (IC50 >10 μ M). Ritlecitinib tosylate rapidly inactivates the JAK3 kinase, and blocks signaling and downstream STAT phosphorylation mediated by common gamma chain cytokines such as IL-2 and IL-15. Ritlecitinib tosylate can inhibit Th1/Th17 cell differentiation and function, and effectively suppress preclinical animal models such as alopecia areata, adjuvant-induced arthritis (AIA), and experimental autoimmune encephalomyelitis (EAE) .
    Ritlecitinib tosylate
  • HY-100754
    Ritlecitinib
    5+ Cited Publications

    PF-06651600

    		 JAK Interleukin Related STAT Inflammation/Immunology
    Ritlecitinib (PF-06651600) is a highly selective, orally active, irreversible covalent JAK3 inhibitor (IC50=33 nM) without inhibitory activity towards JAK1, JAK2, and TYK2 (IC50 >10 μ M). Ritlecitinib rapidly inactivates the JAK3 kinase, and blocks signaling and downstream STAT phosphorylation mediated by common gamma chain cytokines such as IL-2 and IL-15. Ritlecitinib can inhibit Th1/Th17 cell differentiation and function, and effectively suppress preclinical animal models such as alopecia areata, adjuvant-induced arthritis (AIA), and experimental autoimmune encephalomyelitis (EAE) .
    Ritlecitinib
  • HY-100754A
    Ritlecitinib (malonate)

    PF-06651600 (malonate)

    		 JAK Interleukin Related STAT Inflammation/Immunology
    Ritlecitinib (PF-06651600) malonate is a highly selective, orally active, irreversible covalent JAK3 inhibitor (IC50=33 nM) without inhibitory activity towards JAK1, JAK2, and TYK2 (IC50 >10 μ M). Ritlecitinib malonate rapidly inactivates the JAK3 kinase, and blocks signaling and downstream STAT phosphorylation mediated by common gamma chain cytokines such as IL-2 and IL-15. Ritlecitinib malonate can inhibit Th1/Th17 cell differentiation and function, and effectively suppress preclinical animal models such as alopecia areata, adjuvant-induced arthritis (AIA), and experimental autoimmune encephalomyelitis (EAE) .
    Ritlecitinib (malonate)
  • HY-B2132
    Tryptamine
    1 Publications Verification

    3-(2-AminoeTHyl)indole~2-(3-Indolyl)eTHylamine

    		 Endogenous Metabolite 5-HT Receptor Aryl Hydrocarbon Receptor Neurological Disease Metabolic Disease
    Tryptamine is a selective, blood-brain-penetrating 5-HT4 receptor agonist (EC50=1-3 mM) and an endogenous ligand of the aryl hydrocarbon receptor (AHR) (Kd=10-50 nM). Tryptamine promotes intestinal anion secretion and fluid transport by activating G protein-coupled receptors (GPCRs) and accelerates gastrointestinal motility. Tryptamine regulates Th17/Treg balance to inhibit neuroinflammation, competitively binds to 5-HT receptors to regulate central nervous system activity, and participates in temperature regulation and spinal reflex regulation as a neuromodulator. Tryptamine can be used to study intestinal motility disorders such as functional constipation, and has shown significant efficacy in multiple sclerosis models .
    Tryptamine
  • HY-167692
    JI069

    		STAT Others
    JI069 is a novel JAK-STAT inhibitor that demonstrates potent activity in suppressing Th1, Th2, and Th17 differentiation while promoting iTreg differentiation. JI069 effectively inhibits STAT3 activation as well as the activation of other STATs, including STAT1, STAT5, and STAT6. JI069 has shown significant therapeutic potential in alleviating symptoms of collagen-induced arthritis in mice while inhibiting cytokine production from T cells and the phosphorylation of STAT3 in synovial cells.
    JI069
  • HY-120000
    MS402
    1 Publications Verification

    		 Epigenetic Reader Domain Inflammation/Immunology Cancer
    MS402 is a BD1-selective BET BrD inhibitor with Kis of 77 nM, 718 nM, 110 nM, 200 nM, 83 nM, and 240 nM for BRD4(BD1), BRD4(BD2), BRD3(BD1), BRD3(BD2), BRD2(BD1) and BRD2(BD2), respectively. MS402 blocks Th17 cell differentiation and ameliorates colitis in mice .
    MS402
  • HY-16734
    Amiselimod

    MT-1303

    		 LPL Receptor Cardiovascular Disease Inflammation/Immunology
    Amiselimod (MT-1303) is converted to its active metabolite Amiselimod phosphate by sphingosine kinases in vivo. Amiselimod is an orally active and high selectivity sphingosine 1-phosphate receptor-1 (S1P1) agonist, designed to reduce the bradycardia effects associated with fingolimod and other S1P receptor modulators. Amiselimod inhibits chronic colitis via inhibiting infiltration of colitogenic Th1 and Th17 cells into the colon. Amiselimod inhibits lupus nephritis by reducing the infiltration of autoreactive T cells into the kidneys. Amiselimodis promising for research of autoimmune diseases .
    Amiselimod

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: